Literature DB >> 10740989

Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action.

S Kapur1, P Seeman.   

Abstract

RATIONALE AND
OBJECTIVE: While the blockade of dopamine D2 receptors are necessary for antipsychotic action, antipsychotic agents differ nearly a thousand-fold in their affinity for the D2 receptor. This affinity is determined by the rate at which the antipsychotic agent binds to (kon) and the rate at which it dissociates from (koff) the D2 receptors. The objective of this study was to determine the relationship between kon, koff and the affinity (Ki) of antipsychotic agents for the D2 receptors, with particular reference to typical and atypical antipsychotic agents.
DESIGN: The koff of several typical as well as atypical antipsychotic agents (nemonapride, spiperone, haloperidol, chlorpromazine, raclopride, olanzapine, sertindole, clozapine and quetiapine) was measured in vitro using the 3H-radiolabelled analogues of these drugs. The affinity of these drugs for the D2 receptor was determined by competition with 3H-raclopride in vitro. The kon was derived from values of affinity and ++koff. MAIN OUTCOME MEASURES: kon, koff, and the Ki of antipsychotic drugs.
RESULTS: The range of affinity values was similar to that conventionally accepted (0.025-155 nmol/L). The koff values varied a thousand-fold from 0.002 to 3.013 min-1, with relatively little variation in kon. The rate at which antipsychotic agents come off the receptor (koff) accounted for 99% of the variation in their affinity for the D2 receptor; differences in kon did not account for differences in affinity.
CONCLUSIONS: The differences in the affinity of antipsychotic agents are entirely determined by how fast they come off the D2 receptor. These differences in koff may lead to functionally different kinds of dopamine blockade. Drugs with a higher koff will be faster in blocking receptors, and once blocked, will provide more access to surges in dopamine transmission. Since atypical drugs show a lower affinity and a faster dissociation, a higher koff for the D2 receptor is proposed as a mechanism for "atypical" antipsychotic effect.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10740989      PMCID: PMC1408069     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  14 in total

1.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro.

Authors:  V J Cunningham; S P Hume; G R Price; R G Ahier; J E Cremer; A K Jones
Journal:  J Cereb Blood Flow Metab       Date:  1991-01       Impact factor: 6.200

3.  Antipsychotic drug doses and neuroleptic/dopamine receptors.

Authors:  P Seeman; T Lee; M Chau-Wong; K Wong
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

4.  Cloning of the cDNA and gene for a human D2 dopamine receptor.

Authors:  D K Grandy; M A Marchionni; H Makam; R E Stofko; M Alfano; L Frothingham; J B Fischer; K J Burke-Howie; J R Bunzow; A C Server
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 5.  Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors.

Authors:  P Seeman; T Tallerico
Journal:  Mol Psychiatry       Date:  1998-03       Impact factor: 15.992

6.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

7.  Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine.

Authors:  P Seeman; T Tallerico
Journal:  Am J Psychiatry       Date:  1999-06       Impact factor: 18.112

8.  Estimation of haloperidol concentrations in rat striatum after chronic treatment.

Authors:  E P Bellows; D E Barnes; J G Csernansky
Journal:  Brain Res Bull       Date:  1991-05       Impact factor: 4.077

9.  (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled beta-adrenergic antagonists.

Authors:  H Affolter; C Hertel; K Jaeggi; M Portenier; M Staehelin
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

10.  Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis.

Authors:  L Farde; L Eriksson; G Blomquist; C Halldin
Journal:  J Cereb Blood Flow Metab       Date:  1989-10       Impact factor: 6.200

View more
  72 in total

1.  Schizophrenia: more dopamine, more D2 receptors.

Authors:  P Seeman; S Kapur
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

Authors:  Rajiv Tandon
Journal:  Psychiatr Q       Date:  2002

3.  Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship.

Authors:  Euitae Kim; Oliver D Howes; Bo-Hyung Kim; Jae Min Jeong; Jae Sung Lee; In-Jin Jang; Sang-Goo Shin; Federico E Turkheimer; Shitij Kapur; Jun Soo Kwon
Journal:  J Cereb Blood Flow Metab       Date:  2011-12-21       Impact factor: 6.200

4.  Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.

Authors:  Rik de Greef; Alan Maloney; Per Olsson-Gisleskog; Joep Schoemaker; John Panagides
Journal:  AAPS J       Date:  2010-12-24       Impact factor: 4.009

Review 5.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

6.  Estimation of the dissociation rate of unlabelled ligand-receptor complexes by a 'two-step' competition binding approach.

Authors:  A Packeu; M Wennerberg; A Balendran; G Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 7.  The drug-target residence time model: a 10-year retrospective.

Authors:  Robert A Copeland
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

8.  Interaction of clozapine and its nitrenium ion with rat D2 dopamine receptors: in vitro binding and computational study.

Authors:  Sébastien Dilly; Jean-François Liégeois
Journal:  J Comput Aided Mol Des       Date:  2010-12-24       Impact factor: 3.686

Review 9.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

10.  Intermittent treatment with haloperidol or quetiapine does not disrupt motor and cognitive recovery after experimental brain trauma.

Authors:  Jillian J Weeks; Lauren J Carlson; Hannah L Radabaugh; Patricia B de la Tremblaye; Corina O Bondi; Anthony E Kline
Journal:  Behav Brain Res       Date:  2016-09-21       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.